The main objective of this study is to evaluate the safety and tolerability of 12-week oral
CXA-10 therapy in subjects with pulmonary arterial hypertension, with additional evaluation
on the clinical efficacy of oral CXA-10 on changes in hemodynamics, exercise capacity,
cardiovascular function and patient reported outcomes.
Phase:
Phase 2
Details
Lead Sponsor:
Gladwin, Mark, MD University of Pittsburgh
Collaborators:
Complexa, Inc. National Heart, Lung, and Blood Institute (NHLBI)